Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition

  • Song, Kyung Ho (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Jung, Hye-Kyung (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Kim, Hyun Jin (Department of Internal Medicine, Gyeongsang National University, College of Medicine) ;
  • Koo, Hoon Sup (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Kwon, Yong Hwan (Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Shin, Hyun Duk (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lim, Hyun Chul (Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine) ;
  • Shin, Jeong Eun (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Sung Eun (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Cho, Dae Hyeon (Department of Internal Medicine, Sungkyunkwan University School of Medicine) ;
  • Kim, Jeong Hwan (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Hyun Jung (Department of Preventive Medicine, Korea University College of Medicine) ;
  • The Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility (Korean Society of Neurogastroenterology and Motility)
  • Received : 2017.12.14
  • Accepted : 2018.02.27
  • Published : 2018.04.30
⟨ Previous Next ⟩

Abstract

In 2011, the Korean Society of Neurogastroenterology and Motility (KSNM) published clinical practice guidelines on the management of irritable bowel syndrome (IBS) based on a systematic review of the literature. The KSNM planned to update the clinical practice guidelines to support primary physicians, reduce the socioeconomic burden of IBS, and reflect advances in the pathophysiology and management of IBS. The present revised version of the guidelines is in continuity with the previous version and targets adults diagnosed with, or suspected to have, IBS. A librarian created a literature search query, and a systematic review was conducted to identify candidate guidelines. Feasible documents were verified based on predetermined inclusion and exclusion criteria. The candidate seed guidelines were fully evaluated by the Guidelines Development Committee using the Appraisal of Guidelines for Research and Evaluation II quality assessment tool. After selecting 7 seed guidelines, the committee prepared evidence summaries to generate data exaction tables. These summaries comprised the 4 main themes of this version of the guidelines: colonoscopy; a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; probiotics; and rifaximin. To adopt the core recommendations of the guidelines, the Delphi technique (ie, a panel of experts on IBS) was used. To enhance dissemination of the clinical practice guidelines, a Korean version will be made available, and a food calendar for patients with IBS is produced.

Keywords

References

  1. Ballou S, Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol Motil Published Online First: 25 Oct 2016. doi: 10.1111/nmo.12982.
  2. Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ 2017;20:353-362. https://doi.org/10.1080/13696998.2016.1269016
  3. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201. https://doi.org/10.1159/000211715
  4. Lee YY WA, Tan HJ, Chua AS, Whitehead WE. Rome III survey of irritable bowel syndrome among ethnic Malays. World J Gastroenterol 2012;18:6475-6480. https://doi.org/10.3748/wjg.v18.i44.6475
  5. Siah KT, Wong RK, Chan YH, Ho KY, Gwee KA. Prevalence of irritable bowel syndrome in Singapore and its association with dietary, lifestyle, and environmental factors. J Neurogastroenterol Motil2016;22:670-676. https://doi.org/10.5056/jnm15148
  6. Miwa H. Prevalence of irritable bowel syndrome in Japan: internet survey using Rome III criteria. Patient Prefer Adherence 2008;2:143-147.
  7. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology 2016;150:1393-1407. https://doi.org/10.1053/j.gastro.2016.02.031
  8. Kim JH, Lin E, Pimentel M. Biomarkers of Irritable Bowel Syndrome. J Neurogastroenterol Motil 2017;23:20-26. https://doi.org/10.5056/jnm16135
  9. Lee OY, Yoon CO. Review: evidence based guideline for diagnosis and treatment: diagnostic guideline for irritable bowel syndrome. Kor J Neurogastroenterol Motil 2005;11:30-35.
  10. Park HJ. Review: evidence based guideline for diagnosis and treatment: therapeutic guideline for irritable bowel syndrome. Kor J Neurogastroenterol Motil 2005;11:36-43.
  11. Park JH, Byeon JS, Shin WG, et al. Diagnosis of irritable bowel syndrome: a systematic review. Korean J Gastroenterol 2010;55:308-315. https://doi.org/10.4166/kjg.2010.55.5.308
  12. Kwon JG, Park KS, Park JH, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol 2011;57:82-99. https://doi.org/10.4166/kjg.2011.57.2.82
  13. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23. https://doi.org/10.1136/qhc.12.1.18
  14. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839-E842. https://doi.org/10.1503/cmaj.090449
  15. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(suppl 1):S2-S26. https://doi.org/10.1038/ajg.2014.187
  16. Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S; American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1146-1148. https://doi.org/10.1053/j.gastro.2014.09.001
  17. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798. https://doi.org/10.1136/gut.2007.119446
  18. Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ (Clinical research ed) 2015;350:h701. https://doi.org/10.1136/bmj.h701
  19. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-1205. https://doi.org/10.1111/j.1440-1746.2010.06353.x
  20. Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol 2015;50:11-30. https://doi.org/10.1007/s00535-014-1017-0
  21. Harstall C, Taenzer P, Angus DK, Moga C, Schuller T, Scott NA. Creating a multidisciplinary low back pain guideline: anatomy of a guideline adaptation process. J Eval Clin Pract 2011;17:693-704. https://doi.org/10.1111/j.1365-2753.2010.01420.x
  22. Developing NICE guidelines: the manual. London: National Institute for Health and Care Excellence 2015.
  23. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43-II47.
  24. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. The American journal of gastroenterology 2009;104(suppl 1):S1-S35.
  25. Tolliver BA, Herrera JL, DiPalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994;89:176-178.
  26. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002;122:1701-1714. https://doi.org/10.1053/gast.2002.33741
  27. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-672. https://doi.org/10.1136/gut.2003.021857
  28. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-2917. https://doi.org/10.1111/j.1572-0241.1999.01437.x
  29. Kim ES, Cheon JH, Park JJ, et al. Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception. J Gastroenterol Hepatol 2010;25:1232-1238. https://doi.org/10.1111/j.1440-1746.2010.06338.x
  30. Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol 2010;105:652-661. https://doi.org/10.1038/ajg.2009.621
  31. Whitehead WE, Palsson OS, Feld AD, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:137-146. https://doi.org/10.1111/j.1365-2036.2006.02956.x
  32. Black TP, Manolakis CS, Di Palma JA. "Red flag" evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis 2012;21:153-156.
  33. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007;13:175-181. https://doi.org/10.1002/ibd.20059
  34. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75, e5. https://doi.org/10.1053/j.gastro.2013.09.046
  35. Kim HJ. What is the FODMAP? Korean J Medicine 2015;89:179-185. https://doi.org/10.3904/kjm.2015.89.2.179
  36. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012;107:657-666. https://doi.org/10.1038/ajg.2012.49
  37. Iacovou M, Tan V, Muir JG, Gibson PR. The Low FODMAP diet and its application in East and Southeast Asia. J Neurogastroenterol Motil 2015;21:459-470. https://doi.org/10.5056/jnm15111
  38. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012;142:1510-1518. https://doi.org/10.3945/jn.112.159285
  39. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011;24:487-495. https://doi.org/10.1111/j.1365-277X.2011.01162.x
  40. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 2010;25:252-258. https://doi.org/10.1111/j.1440-1746.2009.06149.x
  41. Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011;106:915-922. https://doi.org/10.1038/ajg.2010.480
  42. Daley AJ, Grimmett C, Roberts L, et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008;29:778-782. https://doi.org/10.1055/s-2008-1038600
  43. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154. https://doi.org/10.1136/bmj.b3154
  44. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol 2014;109:1367-1374. https://doi.org/10.1038/ajg.2014.195
  45. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:511-514.
  46. Belsey JD, Geraint M, Dixon TA. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010;64:944-955. https://doi.org/10.1111/j.1742-1241.2010.02397.x
  47. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013;108:1508-1515. https://doi.org/10.1038/ajg.2013.197
  48. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2009;2:221-238. https://doi.org/10.1177/1756283X09104794
  49. Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India 1984;32:1041-1044.
  50. Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988;83:1262-1266.
  51. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011:CD003460.
  52. Annahazi A, Roka R, Rosztoczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol 2014;20:6031-6043. https://doi.org/10.3748/wjg.v20.i20.6031
  53. Wittmann T, Paradowski L, Ducrotte P, Ducrotte L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010;31:615-624. https://doi.org/10.1111/j.1365-2036.2009.04216.x
  54. Everitt H, Moss-Morris R, Sibelli A, et al. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 2013;13:68. https://doi.org/10.1186/1471-230X-13-68
  55. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010;16:547-553. https://doi.org/10.3748/wjg.v16.i5.547
  56. Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-442. https://doi.org/10.1111/j.1365-2036.2011.04730.x
  57. Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol 2015;13:1285-1292, e1. https://doi.org/10.1016/j.cgh.2015.01.015
  58. Awad RA, Cordova VH, Dibildox M, Santiago R, Camacho S. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. Acta Gastroenterol Latinoam 1997;27:247-251.
  59. Kruis W, Weinzierl M, Schussler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986;34:196-201. https://doi.org/10.1159/000199329
  60. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247. https://doi.org/10.1007/BF01296258
  61. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80.
  62. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-84.
  63. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-468. https://doi.org/10.3109/00365529609006766
  64. Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion 2014;89:253-267. https://doi.org/10.1159/000362405
  65. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996;57:478-483. https://doi.org/10.1159/000201377
  66. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-782. https://doi.org/10.1046/j.1365-2036.2000.00762.x
  67. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-855. https://doi.org/10.1046/j.1365-2036.1998.00375.x
  68. Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2017;12:e0172846. https://doi.org/10.1371/journal.pone.0172846
  69. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-235. https://doi.org/10.1159/000150632
  70. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-1211. https://doi.org/10.1080/00365520802240255
  71. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-1104. https://doi.org/10.1111/j.1365-2982.2011.01771.x
  72. Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014;12:953-959, e4. https://doi.org/10.1016/j.cgh.2013.11.024
  73. Fukudo S, Matsueda K, Haruma K, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II study. Neurogastroenterol Motil Published Online First: 16 Feb 2017. doi: 10.1111/nmo.13023.
  74. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology 2016;150:358-366, e8. https://doi.org/10.1053/j.gastro.2015.10.047
  75. Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III longterm study. J Gastroenterol 2016;51:874-882. https://doi.org/10.1007/s00535-016-1165-5
  76. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-2709.
  77. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-380. https://doi.org/10.1016/S0016-5085(98)70203-3
  78. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 2000;118:463-468. https://doi.org/10.1016/S0016-5085(00)70251-4
  79. Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol 2012;18:4994-5013. https://doi.org/10.3748/wjg.v18.i36.4994
  80. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-360. https://doi.org/10.1053/gast.2001.21166
  81. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354. https://doi.org/10.1056/NEJMoa0800670
  82. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, doubleblind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-328. https://doi.org/10.1111/j.1365-2036.2008.03884.x
  83. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-365. https://doi.org/10.1136/gut.2008.162404
  84. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999-e541. https://doi.org/10.1111/j.1365-2982.2012.01983.x
  85. Ke M, Tack J, Quigley EM, et al. Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: a pooled analysis of 4 randomized, placebo-controlled studies. J Neurogastroenterol Motil 2014;20:458-468. https://doi.org/10.5056/jnm14029
  86. Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology 2013;144:218-238. https://doi.org/10.1053/j.gastro.2012.10.028
  87. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-1988. https://doi.org/10.1053/j.gastro.2009.02.074
  88. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010;16:2978-2990. https://doi.org/10.3748/wjg.v16.i24.2978
  89. Nelson TA, Holmes S, Alekseyenko AV, et al. PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. Neurogastroenterol Motil 2011;23:169-177, e141-e162. https://doi.org/10.1111/j.1365-2982.2010.01637.x
  90. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrheapredominant irritable bowel syndrome. Gut pathogens 2010;2:19. https://doi.org/10.1186/1757-4749-2-19
  91. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-419.
  92. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroe 2006;101:326-333. https://doi.org/10.1111/j.1572-0241.2006.00458.x
  93. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-563. https://doi.org/10.7326/0003-4819-145-8-200610170-00004
  94. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32. https://doi.org/10.1056/NEJMoa1004409
  95. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151:1113-1121. https://doi.org/10.1053/j.gastro.2016.08.003
  96. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-1172, e2. https://doi.org/10.1053/j.gastro.2014.09.002
  97. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35. https://doi.org/10.1038/ajg.2011.355
  98. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590. https://doi.org/10.1111/j.1572-0241.2006.00734.x
  99. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;33:1123-1132. https://doi.org/10.1111/j.1365-2036.2011.04633.x
  100. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-394. https://doi.org/10.1111/j.1365-2036.2005.02579.x
  101. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-1147. https://doi.org/10.1097/00042737-200110000-00004
  102. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238. https://doi.org/10.1111/j.1572-0241.2000.02015.x
  103. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904. https://doi.org/10.1046/j.1365-2036.2003.01543.x
  104. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-2620. https://doi.org/10.1023/A:1020597001460
  105. Kim YG, Moon JT, Lee KM, Chon NR, Park H. [The effects of probiotics on symptoms of irritable bowel syndrome.] Korean J Gastroentero 2006;47:413-419. [Korean]
  106. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-683. https://doi.org/10.1097/MCG.0b013e318204593e
  107. Cha BK, Jung MS, Choi CH, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-227. https://doi.org/10.1097/MCG.0b013e31823712b1
  108. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555-564. https://doi.org/10.1016/S0140-6736(02)09712-X
  109. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31. https://doi.org/10.1016/S0016-5085(03)00669-3
  110. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-228. https://doi.org/10.1016/S1542-3565(03)70039-1
  111. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:678-684. https://doi.org/10.1111/j.1365-2036.2008.03633.x
  112. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-920. https://doi.org/10.1111/j.1572-0241.2004.04127.x
  113. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103.
  114. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. Scand J Gastroenterol 1982;17:871-875. https://doi.org/10.3109/00365528209181108
  115. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378. https://doi.org/10.1136/gut.2008.163162
  116. Xie C, Tang Y, Wang Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One 2015;10:e0127815. https://doi.org/10.1371/journal.pone.0127815
  117. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-166.
  118. Halpert A, Dalton CB, Diamant NE, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005;100:664-671. https://doi.org/10.1111/j.1572-0241.2005.30375.x
  119. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007:CD005454.
  120. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1350-1365. https://doi.org/10.1038/ajg.2014.148
  121. Sohn W, Lee OY, Kwon JG, et al. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, openlabel, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012;24:860-e398. https://doi.org/10.1111/j.1365-2982.2012.01945.x
  122. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696. https://doi.org/10.1111/j.1365-2036.2008.03629.x
  123. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-341. https://doi.org/10.1111/j.1365-2036.2008.03881.x
  124. Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994;62:576-582. https://doi.org/10.1037/0022-006X.62.3.576
  125. Heitkemper MM, Jarrett ME, Levy RL, et al. Self-management for women with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:585-596. https://doi.org/10.1016/S1542-3565(04)00242-3
  126. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991;100:450-457. https://doi.org/10.1016/0016-5085(91)90215-7
  127. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-317. https://doi.org/10.1053/gast.2003.50055
  128. Simren M1, Ringstrom G, Bjornsson ES, Abrahamsson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom Med 2004;66:233-238. https://doi.org/10.1097/01.psy.0000116964.76529.6e
  129. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003;98:2209-2218. https://doi.org/10.1111/j.1572-0241.2003.07716.x
  130. Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ 2005;331:435. https://doi.org/10.1136/bmj.38545.505764.06
  131. Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:937-947, e4. https://doi.org/10.1016/j.cgh.2015.11.020
  132. Altayar O, Sharma V, Prokop LJ, Sood A, Murad MH. Psychological therapies in patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2015;2015:549308.
  133. Blanchard EB, Schwarz SP, Suls JM, et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther 1992;30:175-189. https://doi.org/10.1016/0005-7967(92)90141-3
  134. Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998;23:219-232. https://doi.org/10.1023/A:1022209631047
  135. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008;134(suppl 1):545.
  136. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332. https://doi.org/10.1136/gut.2008.167270
  137. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-1561. https://doi.org/10.1038/ajg.2014.202
  138. Enck P1, Zimmermann K, Menke G, Muller-Lissner S, Martens U, Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008;20:1103-1109. https://doi.org/10.1111/j.1365-2982.2008.01156.x
  139. Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011;45:518-525. https://doi.org/10.1097/MCG.0b013e31820ca4d6
  140. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009;29:104-114. https://doi.org/10.1111/j.1365-2036.2008.03853.x

Cited by

  1. Review of the Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition vol.72, pp.5, 2018, https://doi.org/10.4166/kjg.2018.72.5.252
  2. Sex-Gender Differences in Irritable Bowel Syndrome vol.24, pp.4, 2018, https://doi.org/10.5056/jnm18082
  3. Effect of antispasmodic agents for the treatment of irritable bowel syndrome vol.61, pp.7, 2018, https://doi.org/10.5124/jkma.2018.61.7.428
  4. Efficacy of different probiotic protocols in irritable bowel syndrome : A network meta-analysis vol.98, pp.27, 2019, https://doi.org/10.1097/md.0000000000016068
  5. Irritable Bowel Syndrome vol.73, pp.2, 2018, https://doi.org/10.4166/kjg.2019.73.2.84
  6. Can Certain Foods Cause Gastrointestinal Symptoms in Korean Patients With Irritable Bowel Syndrome? vol.25, pp.2, 2018, https://doi.org/10.5056/jnm19052
  7. Bacillus spp. Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome vol.11, pp.9, 2018, https://doi.org/10.3390/nu11091968
  8. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review vol.7, pp.21, 2018, https://doi.org/10.12998/wjcc.v7.i21.3469
  9. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review vol.7, pp.21, 2018, https://doi.org/10.12998/wjcc.v7.i21.3486
  10. Clinical Practice Guidelines for Functional Dyspepsia in Korea vol.26, pp.1, 2018, https://doi.org/10.5056/jnm19209
  11. 2019 Seoul Consensus on Esophageal Achalasia Guidelines vol.26, pp.2, 2020, https://doi.org/10.5056/jnm20014
  12. Effect of a Synbiotic Containing Lactobacillus paracasei and Opuntia humifusa on a Murine Model of Irritable Bowel Syndrome vol.12, pp.10, 2020, https://doi.org/10.3390/nu12103205
  13. Effect of Heat-Killed Lactobacillus casei DKGF7 on a Rat Model of Irritable Bowel Syndrome vol.13, pp.2, 2018, https://doi.org/10.3390/nu13020568
  14. Clinical Practice Guidelines for the Treatment of Functional Dyspepsia in Korea vol.96, pp.2, 2021, https://doi.org/10.3904/kjm.2021.96.2.116
  15. 과민대장증후군(Irritable Bowel Syndrome)의 한의임상 진료현황에 대한 설문조사 연구 vol.42, pp.4, 2021, https://doi.org/10.22246/jikm.2021.42.4.532
  16. Long‐term symptom severity in people with irritable bowel syndrome following dietetic treatment in primary care: A service evaluation vol.34, pp.5, 2018, https://doi.org/10.1111/jhn.12860
  17. World Gastroenterology Organisation Global Guidelines : Diet and the Gut vol.56, pp.1, 2018, https://doi.org/10.1097/mcg.0000000000001588